{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:34:26Z","timestamp":1768534466235,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to develop a user-friendly prediction formula for dose rate adjustment after initial <jats:sup>177<\/jats:sup>Lu-Dotatate therapy from a prospective observational study of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>This study included consenting patients in a prospective observational study who underwent their first\u00a0treatment in four cycles of <jats:sup>177<\/jats:sup>Lu-Dotatate treatment at our hospital between January 2022 and February 2024. All patients received 7.4\u00a0GBq of <jats:sup>177<\/jats:sup>Lu-Dotatate. The prediction formula was derived from the regression analysis of tumor-related factors and renal function. Creatinine clearance was estimated using the Cockcroft\u2013Gault equation in this study for renal function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 13 patients (seven males, six females, median age: 59\u00a0years), logarithmically transformed total tumor volume (cc) and maximum tumor diameter (mm) of primary tumors or metastases showed strong correlations (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, R<jats:sup>2<\/jats:sup>\u2009=\u20090.897). As such, the maximum tumor diameter was used as the tumor parameter in the prediction formula. Additionally, maximum tumor diameter and creatinine clearance showed strong (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, R<jats:sup>2<\/jats:sup>\u2009=\u20090.768) and moderate (<jats:italic>p<\/jats:italic>\u2009=\u20090.013, R<jats:sup>2<\/jats:sup>\u2009=\u2009445) correlations, respectively, with the ratio of the dose rate 5.5-h post-administration to the dose rate immediately post-administration (%) at 1\u00a0m from the body surface. The resulting formula, 51.4\u2009+\u20090.360\u2009\u00d7\u2009maximum tumor diameter (mm) \u2212 0.212\u2009\u00d7\u2009creatinine clearance (ml\/min), demonstrated an extremely strong correlation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, R<jats:sup>2<\/jats:sup>\u2009=\u20090.937).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present study showed that the maximum tumor diameter and renal function affected the declining the dose rate of patients surface after <jats:sup>177<\/jats:sup>Lu-Dotatate, which can inform post-administration dose rate management and potentially facilitate outpatient treatment in Japan.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11604-024-01585-5","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T06:03:07Z","timestamp":1715320987000},"page":"1031-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Maximum tumor diameter and renal function can predict the declining surface dose rate after 177Lu-Dotatate: preliminary results of single institution in Japan"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1158","authenticated-orcid":false,"given":"Takashi","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Tanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Kanezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"issue":"12","key":"1585_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770\u201386.","journal-title":"Mod Pathol"},{"issue":"10","key":"1585_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1585_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24750","volume":"4","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4(9): e2124750.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1585_CR4","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1186\/s12885-020-07581-y","volume":"20","author":"T Masui","year":"2020","unstructured":"Masui T, Ito T, Komoto I, Uemoto S, JNETS Project Study Group. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20(1):1104.","journal-title":"BMC Cancer"},{"issue":"5","key":"1585_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.pan.2020.06.002","volume":"20","author":"M Ikeda","year":"2020","unstructured":"Ikeda M, Morizane C, Hijioka S, Matsumoto S, Konishi T, Komoto I, et al. Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology. 2020;20(5):944\u201350.","journal-title":"Pancreatology"},{"issue":"24","key":"1585_CR6","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1200\/JCO.22.00176","volume":"40","author":"TA Hope","year":"2022","unstructured":"Hope TA, Pavel M, Bergsland EK. Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time? J Clin Oncol. 2022;40(24):2818\u201329.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1585_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"1585_CR8","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u201363.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1585_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/jhbp.1101","volume":"29","author":"A Kudo","year":"2022","unstructured":"Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takanoet S, et al. Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1\/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci. 2022;29(4):487\u201399.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"8","key":"1585_CR10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of [177Lu] Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50(8):2486\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"1585_CR11","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, Herderet WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1585_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.122.263856","volume":"64","author":"NS Minczeles","year":"2023","unstructured":"Minczeles NS, de Herder WW, Feelders RA, Verburg FA, Hofland J, Brabander T, et al. Long-term outcomes of submaximal activities of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients. J Nucl Med. 2023;64(1):40\u20136.","journal-title":"J Nucl Med"},{"key":"1585_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin DM, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.LBA588.","journal-title":"J Clin Oncol"},{"key":"1585_CR14","doi-asserted-by":"crossref","unstructured":"Japan Isotope Association Faculty of Medicine and Pharmacy, National Nuclear Medicine Practice Survey Specialist Committee. The present state of nuclear medicine practice in Japan; A report of the 9th nationwide survey in 2022. Radioisotopes. 2023; 72(1): 49\u2013100.","DOI":"10.3769\/radioisotopes.72.49"},{"key":"1585_CR15","unstructured":"Regarding discharge of patients who have received radiopharmaceuticals: Ministry of Health, Labour and Welfare in Japan. https:\/\/www.mhlw.go.jp\/content\/10800000\/001063188.pdf (13 February 2024, data last accessed)"},{"issue":"13","key":"1585_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, Eijck CH, Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol"},{"key":"1585_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf (13 February 2024, data last accessed)"},{"key":"1585_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"issue":"23","key":"1585_CR19","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.3390\/cancers14235792","volume":"14","author":"MN Becx","year":"2022","unstructured":"Becx MN, Minczeles NS, Brabander T, Herder WW, Nonnekens J, Hofland J. A clinical guide to peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients. Cancers (Basel). 2022;14(23):5792.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1585_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/HP.0000000000001700","volume":"125","author":"Y Ni","year":"2023","unstructured":"Ni Y, Ye Q, Liu X, Wang K, Yu F, Fu J, et al. 177 Lu-DOTATATE therapy: effects of water intake and drinking duration on patient peripheral dose equivalent rates. Health Phys. 2023;125(3):155\u20138.","journal-title":"Health Phys"},{"issue":"1","key":"1585_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/1099800414531483","volume":"17","author":"S Kim","year":"2015","unstructured":"Kim S, Byun Y. Comparison of renal function indicators according to hydration volume in patients receiving intravenous acyclovir with CNS infection. Biol Res Nurs. 2015;17(1):55\u201361.","journal-title":"Biol Res Nurs"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01585-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-024-01585-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01585-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:10:57Z","timestamp":1724998257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-024-01585-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1007\/s11604-024-01585-5","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This prospective study was approved by the Institutional Ethics Committee of the Faculty of Medicine at Yamagata University (approval number: 2021-297). The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients agreed to this prospective observational study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}